Participated · Series A · Jan 2026

Spiro Medical is a venture-backed medical device company based in Irvine, California that is building the first purpose-built Pulmonary Neuromodulation System (PNM) for asthma patients. The proprietary implant targets neural reflex pathways in the lungs with the goal of reducing symptoms such as wheezing, shortness of breath, and coughing. Founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D., the company enters the market with issued patents and initial human data supporting the technology’s clinical potential. Proceeds from its recent financing will fund final system design, clinical trials, and U.S. regulatory work. Leadership claims deep expertise in implantable neuromodulation, positioning the team to build a “world-class” product. Although the company is pre-revenue, it is targeting a large addressable market of more than 28 million U.S. asthma sufferers and 300 million patients worldwide.

Participated · Series B · Dec 2025

Sanegene Bio is a biotechnology firm focused on creating RNA interference (RNAi) medicines that target metabolic, cardiovascular, and autoimmune disorders. Its proprietary delivery platform is aimed at improving the clinical utility of RNA-based therapeutics, an area that is experiencing heightened global momentum. The company plans to use its latest capital infusion to advance multiple RNAi programs into registration studies, signaling a move toward late-stage clinical development. Management also intends to broaden the pipeline into additional disease areas within its core therapeutic focus. Although specific revenue or patient enrollment figures were not disclosed, the sizable financing underscores investor confidence in Sanegene Bio’s approach and delivery technology. With substantial strategic backing from industry leaders such as Eli Lilly and repeat participation from prior investors, the company is positioned to accelerate development and expand partnership opportunities.

Led · Series B · Sep 2025

iRegene develops induced pluripotent stem cell (iPSC)-derived therapies, with flagship NouvNeu001 (dopaminergic progenitor cells) for Parkinson’s disease and NouvSight001 for retinal degeneration. NouvNeu001 is clinical-stage, received regulatory clearance to begin trials in China and the U.S., and was granted FDA Fast Track Designation in August 2025. The company reported Phase I results showing strong safety and tolerability up to 15 months, PET-confirmed long-term survival of transplanted cells, motor-function improvements, and that patients did not require immunosuppressants after month six. iRegene launched a multicenter Phase II trial in China in April 2025. The business uses a chemically induced platform intended to produce scalable, cost-effective off-the-shelf cell products. Financially, it completed a Series B+ financing raising over RMB 300 million (about $40 million) to fund global clinical programs, early research, team expansion, manufacturing scale-up, and international expansion.

Participated · Equity · Apr 2025

VOC.AI builds AI-powered customer-service solutions centered on its AI Digital Employee and flagship product Solvea, which combines generative AI, a multi-agent architecture, and an e-commerce knowledge graph. The platform delivers omnichannel, multilingual AI agents that handle complex interactions, enterprise-grade compliance (ISO 27001, SOC2, GDPR), and cross-border returns. VOC.AI employs a pay-per-actual-service-results model and provides AI Agent services to more than 100 top brands. The company emphasizes improving workforce efficiency by automating repetitive tasks so human teams can focus on higher-value work. VOC.AI plans to accelerate development of AI-enabled agents and next-generation AI capabilities while expanding localized operations in markets including North America and Japan. The company announced a $15 million funding round to support global growth and product development.

Participated · Series B · Aug 2024

Founded in 2017, H-Chip focuses on the design, development and production of micro-nano structure optical chips and laser chips, positioned upstream in optoelectronics chip manufacturing. Its core products include coining templates, nanometer waveguides, metastructures/surfaces, multilayer films, and optical quantum devices used in optical communication, virtual reality, lidar, and smart sensors. The company operates a 1,500 square meter ultra-clean laboratory and an 18,000 square meter industrialization base, and it manages innovation centers including the high-end optoelectronic chip Innovation Center in Tianjin/Tsinghua University and the micro-nano optoelectronic technology Laboratory of the Jingjinji National Center of Technology Innovation. H-Chip completed a B round financing of nearly RMB 100 million; the proceeds will mainly fund construction of optoelectronic chip industrialization projects. The first phase of that industrialization project is expected to be completed and put into operation in the second half of 2022, with an annual production capacity projected at RMB 1 billion.